The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
Country United States of America
Visit trial
Trial Details
Trial Number
Sponsors & Collaborators
Yale UniversityThe Yale Psychedelic Science Group was established in 2016.